Aarti Drugs announced that the Board of Directors of the Company at its meeting held on 3 February 2026, inter alia, have recommended the interim dividend of Rs 2 per equity Share (i.e. 20%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Net profit of Aarti Drugs rose 9.42% to Rs 40.54 crore in the quarter ended December 2025 as against Rs 37.05 crore during the previous quarter ended December 2024. Sales rose 8.10% to Rs 601.71 crore in the quarter ended December 2025 as against Rs 556.60 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales601.71556.60 8 OPM %9.1511.09 - PBDT46.9764.56 -27 PBT29.0250.76 -43 NP40.5437.05 9 Powered by Capital Market - Live News

Net profit of Aarti Drugs declined 12.17% to Rs 33.84 crore in the quarter ended December 2025 as against Rs 38.53 crore during the previous quarter ended December 2024. Sales rose 2.77% to Rs 528.80 crore in the quarter ended December 2025 as against Rs 514.54 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales528.80514.54 3 OPM %8.0011.71 - PBDT36.5864.05 -43 PBT21.7152.03 -58 NP33.8438.53 -12 Powered by Capital Market - Live News

Aarti Drugs will hold a meeting of the Board of Directors of the Company on 3 February 2026.Powered by Capital Market - Live News

Net profit of Aarti Drugs rose 29.33% to Rs 45.28 crore in the quarter ended September 2025 as against Rs 35.01 crore during the previous quarter ended September 2024. Sales rose 9.10% to Rs 652.79 crore in the quarter ended September 2025 as against Rs 598.33 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales652.79598.33 9 OPM %12.9111.21 - PBDT76.6759.60 29 PBT60.4145.88 32 NP45.2835.01 29 Powered by Capital Market - Live News